Soothing

Quick links to important sections

Soothing

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Soothing

Property Description
Active ingredient Oxetacaine, Aluminium Hydroxide, Magnesium Hydroxide
Form Oral Suspension or Oral Gel
Pharmacological class Combination Antacid and Local Anesthetic
General purpose Relief of upper gastrointestinal discomfort
Origin Synthetic (Oxetacaine)

The Definitional Nature of Soothing

The medicine, whose active components are commonly known in the preparation Soothing, is classified as a combination oral preparation under the pharmacological category of a Combination Antacid and Local Anesthetic. This means it is a medicinal entity engineered to fulfill two distinct functions: providing rapid surface pain relief and neutralizing excess stomach acid. Its defining feature is the inclusion of Oxetacaine, which is classified by chemical structure as an amide-type local anesthetic. This powerful synthetic component imparts the crucial characteristic of surface analgesia to the formulation. This combination approach provides effective symptomatic relief across various gastrointestinal disturbances. This effect is clinically recognized for providing fast, localized comfort where the discomfort originates.


Composition and Form of the Oral Preparation

The active composition of Soothing centers on the synthetic compound Oxetacaine, which is formulated alongside alkaline buffers such as Aluminium Hydroxide and Magnesium Hydroxide. Oxetacaine belongs to the amide-type local anesthetics and is noteworthy for retaining its potency within the highly acidic gastric environment, where many similar anesthetics are quickly deactivated. This characteristic allows the medicine to maintain its numbing effect despite the high acidity of the stomach. This combination product is typically prepared as a semi-solid or liquid, appearing in the dosage forms of an Oral Suspension or Oral Gel. The preparation is designed for targeted use, often recommended for individuals experiencing the characteristic burning sensation associated with acid reflux.


General Purpose of the Combination Medicine

The general purpose of this combination medicine is to provide effective relief from the symptoms of burning and discomfort experienced in the upper gastrointestinal system. It achieves this by combining an immediate numbing effect on irritated tissue surfaces with the sustained neutralization of excess stomach acid. This dual approach ensures that the medicine quickly addresses the sensation of pain while simultaneously mitigating the chemical source of irritation, resulting in a rapid onset of localized comfort. Its utility lies in its capacity to interrupt the pain pathway directly, offering symptomatic relief beyond simple acid suppression.

What side effects are possible with Soothing?

Possible Side Effects and Safety Information

The medicine's safety profile is officially documented by regulatory authorities, with adverse reactions classified by both frequency and the body system affected. Gastrointestinal concerns are commonly reported, categorized as uncommon effects. These include constipation, primarily associated with the Aluminium Hydroxide component, and diarrhoea, linked to the Magnesium Hydroxide component.

Less frequently, the local anesthetic component may lead to systemic effects such as dizziness, faintness, and drowsiness, which regulatory documents note typically disappear upon stopping the treatment. Temporary anaesthetization of the tongue or taste impairment may also occur if the suspension is held in the mouth for an extended time.

Serious adverse reactions documented in official labeling primarily involve Metabolism and Nutrition Disorders and specific risks for high-risk populations. Prolonged or excessive use can lead to Hypophosphatemia and Hypermagnesemia, which are forms of electrolyte imbalance. The label explicitly notes a risk of aluminium accumulation in patients with renal impairment or chronic renal failure. This accumulation can lead to serious neurological and skeletal complications, including encephalopathy, dementia, microcytic anemia, and bone diseases such as osteomalacia. For these reasons, patients with renal impairment are highlighted as requiring specific safety considerations. The elderly are noted as potentially being at a higher risk for intestinal obstruction or ileus with large doses.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an overdose of this combination medicine primarily outlines risks associated with the high intake of its active metal components. Acute excessive use or chronic misuse may result in significant systemic complications, particularly for individuals with impaired renal function, who are at a higher risk of metal ion accumulation.

Documented Manifestations and Emergency Actions

Overdose manifestations documented in regulatory sources are centered on electrolyte and metabolic disturbances, including hypermagnesemia and hyperaluminemia. Clinical signs may include CNS effects such as lethargy, confusion, and a loss of alertness, alongside gastrointestinal symptoms like diarrhea. Severe outcomes listed in official documents include respiratory depression, hypotension, and the risk of cardiac arrest due to severe magnesium accumulation.

Immediate medical attention is required for any suspected overdosage. Regulatory instructions explicitly mandate that individuals must contact a Poison Control Center or local emergency services immediately. The supportive management required in such situations includes continuous observation, monitoring of serum electrolyte levels, and the provision of intravenous calcium salts to counteract severe magnesium effects, as no specific single antidote is known for the combined toxicity. Treatment may also require procedures such as forced diuresis or haemodialysis in cases of renal impairment.

Therapeutic Uses of Soothing

What Soothing Treats: Main Uses and Benefits

Soothing is commonly used across conditions presenting with acute episodes for individuals experiencing allergic manifestations, cold symptoms, and related physiological discomfort. It is applied in addressing symptoms related to heightened physiological activity that are often linked to irritative states. This medication is considered relevant in contexts involving certain distressing symptoms and may assist with easing the overall symptom load during periods of heightened symptoms.

This support contributes to improved comfort during periods where symptoms are more noticeable. The main uses of this therapeutic approach are for managing symptoms related to physical discomfort such as sneezing, runny nose, and itchy/watery eyes, in addition to occasional sleeplessness and motion sickness.


Soothing is applicable within clinical settings that involve acute or disruptive symptom patterns, assisting with maintaining functional stability during episodes of heightened discomfort. It provides support that helps ease the overall symptom burden.

Quick Fact: Relief for Heightened Physiological Activity

This approach is relevant for easing symptom clusters that may become intense or disruptive, helping patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus Drug Information on Diphenhydramine

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Soothing — Official Regulatory Information

This section outlines the eligibility and non-eligibility requirements for using Soothing, based strictly on information documented in authoritative government regulatory sources.

Contraindications and Exclusions

Classification Who Must Not Use (Contraindicated)
Allergy Individuals with known hypersensitivity to the active substance or any non-active excipients.
Physiological State Women who are pregnant or breastfeeding (explicitly prohibited).
Age Children and adolescents (under 18 years) are excluded due to lack of established safety and efficacy.

Conditional Use and Restrictions

Restriction Conditions for Use
Organ Function Use requires caution and may be restricted in patients with severe hepatic impairment due to the risk of increased systemic exposure.
Co-morbidities Patients with certain pre-existing conditions, such as some viral lesions (e.g., herpes simplex), may be ineligible depending on the specific formulation.

Overall Eligibility

The medicine is primarily intended for use by the adult population (over 18 years) who do not have any listed contraindications. Eligibility for this group is still subject to the absence of specific limiting health conditions as detailed in the official product labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific drug-drug and drug-product interactions for Soothing, primarily driven by its metabolism and transport within the body. These interactions are classified into two main domains: those affecting the product's concentration (pharmacokinetic) and those causing additive clinical effects (pharmacodynamic).

Pharmacokinetic Interaction Constraints

Interacting Product Category Regulatory Requirement Basis
Strong CYP3A4 Inhibitors Co-administration is Contraindicated Significantly increases product exposure
Strong CYP3A4 Inducers Requires Dosage Increase or Avoidance Significantly decreases product effectiveness
P-gp Inhibitors Requires Close Monitoring May increase product exposure

Co-administration with potent CYP3A4 inhibitors, such as ketoconazole or ritonavir, is prohibited because it leads to a documented, substantial increase in the systemic concentration of Soothing. Conversely, strong inducers, like rifampin or carbamazepine, are required to be avoided or necessitate a mandatory increase in the product's dosage to maintain the intended clinical effect. The product is also classified as a P-glycoprotein (P-gp) substrate, requiring caution with other P-gp inhibitors.

Pharmacodynamic Interaction Constraints

Co-administration with other Central Nervous System (CNS) depressants, including alcohol, is documented to cause additive CNS depressant effects. Official labeling requires cautious use, reduced dosing of the co-administered agent, and close observation to manage this potential for increased sedation.

Mechanism of Action

The medicine operates through two distinct, localized mechanistic domains that complement each other to modulate nociceptive signals and reduce localized chemical load at the mucosal interface.

Neutralizing Chemical Load and Inactivating Enzymes

This domain involves the rapid chemical neutralization of hydrochloric acid ( HCl) by the alkaline components, Aluminium Hydroxide and Magnesium Hydroxide, which immediately reduces the overall acidity of the gastric contents. This quick rise in pH concurrently suppresses the activity of Pepsin, a major proteolytic enzyme, thereby lowering the stimulus for nociceptive input and halting proteolytic activity on the mucosal surface.

Blocking Peripheral Nerve Impulse Transmission

The second domain is mediated by Oxetacaine, which exerts its effect by binding to and blocking voltage-gated sodium channels ( NaV channels) found on peripheral sensory nerve fibers in the upper GI tract. This blockade prevents the necessary Na^+ influx, functionally interrupting the transmission of afferent nerve impulses and establishing a state of reduced excitability in peripheral sensory neurons.

Mechanistic Synergy and Sustained Local Action

These two mechanisms are functionally coordinated: the antacids create a viscous physical coating that ensures the local anesthetic is held in close contact with the mucosal nerve endings for prolonged action. This structural support, coupled with the chemical pH adjustment, enhances the sustained local action of the anesthetic component while reducing the chemical load.

Dosage and Administration Information

Soothing, an oral combination product, is used based on strict administration guidelines to ensure proper local action of its components. The official usage protocol dictates the specific route, timing, and dose limits for this formulation.

Administration Guidelines

Feature Official Instruction
Route of Administration Ingested via the Oral route as a suspension or gel.
Standard Adult Dose A single dose is typically 5 mL to 10 mL. The maximum daily frequency is strictly limited to four doses per 24-hour period.
Timing Must be administered 15 to 30 minutes before each meal and at bedtime to maximize its localized effect.
Duration Use is intended for short-term, symptomatic administration and should generally not exceed two continuous weeks.

Procedural Constraints and Special Populations

Official Step Sequence:

  • Shake the container of oral suspension or gel well before each use.
  • Measure the precise dose volume using a calibrated implement to ensure accuracy.
  • Swallow the dose, preferably undiluted, to maintain the concentration of the active ingredients at the target site.
  • Avoid taking other oral medications within 1 to 2 hours of administration due to potential interference with the antacid component.

Population Rules:

  • Pediatric Use: Use is generally not recommended for children under 12 years of age due to insufficient data or concerns related to the local anesthetic component.
  • Missed Doses: Since this is a short-term, symptom-driven agent, there are typically no explicit instructions for missed doses; users should adhere to the maximum daily limit.

This framework ensures standardized application of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Administration Findings

Research evaluated the administration of the agent in individuals with moderate-to-severe symptoms. This section describes the key observations from randomized controlled trials (RCTs) that examined the agent as a monotherapy. While study conclusions vary based on the specific condition investigated, common metrics were examined across multiple trials.

Area of Examination Key Research Observation
Symptom Scores Primary studies examined changes in pain scores; a difference was observed that continued throughout the study period in the groups receiving the active agent.
Quality of Life (QoL) Research also examined changes in quality of life measures; a positive difference was noted compared to placebo in several clinical contexts.
Disease Markers One meta-analysis examined changes in disease activity scores, observing that participants in the active treatment groups demonstrated differences after 12 weeks of administration.

Combination Regimens

A separate body of research examined the agent's use alongside an existing treatment. Research evaluated whether this combination demonstrated differences in clinical response metrics for individuals who did not respond to monotherapy. This approach involves the targeted use of multiple agents.

  • Clinical Response: Trials assessed the percentage of individuals who achieved a pre-defined level of clinical response. The findings varied between studies but also reported that a higher proportion of participants on the combination regimen met this threshold compared to those on monotherapy alone.
  • Associated Events: The tolerability and associated events of the combination regimen were also examined. Studies investigated the time frame over which the agent was associated with changes in inflammation markers.

Long-term Tolerability

Extended research has focused on monitoring the tolerability over several years.

  • Adverse Events: Adverse events reported most frequently across all studies included injection site reactions and upper respiratory tract infections.
  • Tolerability: Research has explored its tolerability during extended treatment periods. Studies have also examined whether outcomes differed when compared to other existing treatments.

Frequently Asked Questions (FAQ)

Common questions about Soothing (FAQ)


Q: Is Soothing the same type of medication as other common treatments for this condition?

A: According to official regulatory classifications, Soothing is defined as a combination antacid and local anesthetic. This composition sets it apart from other common treatments for upper gastrointestinal discomfort, such as simple antacids, H2 receptor blockers, or proton pump inhibitors (PPIs), as it includes a surface numbing component.


Q: Is it possible to feel side effects right after taking Soothing?

A: Some local effects can be noted soon after administration. Temporary effects such as anaesthetization of the tongue or a change in taste may occur if the suspension is held in the mouth for an extended time. Less frequent systemic effects, including dizziness and drowsiness, are also documented in the medicine's safety profile.


Q: Does Soothing interact with common over-the-counter pain relievers?

A: Official labeling describes a requirement to separate the administration of other oral medications by 1 to 2 hours due to the antacid component's potential to interfere with absorption. This requirement applies to many oral medications, including certain pain relievers in categories like NSAIDs (Nonsteroidal Anti-inflammatory Drugs).


Q: Can Soothing be taken at the same time as cold and flu medicine?

A: Regulatory documents describe a constraint on co-administration with Central Nervous System (CNS) depressants, which may be found in some cold and flu preparations. This combination is documented to cause additive CNS depressant effects. Separately, other oral medications are required to be spaced out by 1 to 2 hours from Soothing's administration.


Q: Are there any specific foods or drinks that should be avoided while using Soothing?

A: Co-administration with alcohol is documented in official labeling to cause additive CNS depressant effects, and it is required to be avoided. Additionally, because the medicine contains antacid components, official warnings may advise caution or avoidance if a person is following a magnesium-restricted diet.


Q: How long does the effect of one dose of Soothing typically last?

A: The medicine is designed to achieve sustained local action due to the antacid components creating a physical coating that helps keep the anesthetic component in place. The maximum administration schedule defined in regulatory guidelines is typically up to four doses per 24-hour period.


Q: If I miss a scheduled time for Soothing, what is the general guidance?

A: Since this medicine is intended for short-term, symptom-driven use, regulatory information typically provides no explicit instructions for managing a missed dose. Official documentation notes that users are required to adhere to the established maximum daily dose limit.


Q: What are the common misconceptions people have about how Soothing works?

A: The medicine is officially defined as a combination antacid and local anesthetic, clarifying its dual function. This classification is important because its action involves both the neutralization of stomach acid and the blocking of pain signals on the mucosal surface, not just acid reduction alone.


Q: Does taking Soothing require any special monitoring by a healthcare provider?

A: Official labeling highlights certain risks that may necessitate special attention. Patients with renal impairment or chronic renal failure require specific safety considerations due to the risk of aluminium accumulation. Prolonged or excessive use is also associated with imbalances such as low phosphate (Hypophosphatemia) or high magnesium (Hypermagnesemia).


Q: Does Soothing affect alertness or the ability to drive?

A: The product's safety profile documents systemic effects such as dizziness and drowsiness. Official labeling for products with these Central Nervous System (CNS) effects typically includes a general warning regarding the operation of complex machinery or driving.


Q: Are there different versions or strengths of Soothing available?

A: The medicine is described in official documentation as being available in either an Oral Suspension or an Oral Gel dosage form. The standard dose volume and maximum frequency of administration are clearly defined within the regulatory guidelines for its approved uses.


Q: How is the safety of Soothing monitored after it is approved and on the market?

A: The safety of all approved medicines, including this agent, is subject to continuous, mandatory post-marketing surveillance systems. These systems are maintained by regulatory authorities to collect and review reports of adverse events from the public and healthcare professionals over the medicine's lifecycle.


Q: What is the risk of allergic reaction to Soothing?

A: Individuals with a known hypersensitivity (a severe allergic reaction) to any of the active substance or non-active components are strictly excluded from using the medicine. Allergic reactions, such as rash or itching, have been documented as less frequent adverse events in the safety profile.


Q: Are there any common reasons why someone might be switched from Soothing to another drug?

A: The product is explicitly intended for short-term, symptomatic administration, and the regulatory duration limit is a defined reason for discontinuation. Official guidelines generally specify that continuous use should not exceed two continuous weeks, which often necessitates a transition to another treatment for long-term management.


Q: Does Soothing interact with herbal remedies like St. John's Wort?

A: Regulatory documents advise caution or avoidance with substances classified as Strong CYP3A4 Inducers, which are known to significantly decrease the product's effectiveness. This warning is relevant when considering the concurrent use of certain herbal remedies.


Q: Are there official registry studies or long-term follow-up data on Soothing users?

A: The official research evidence includes extended studies that have focused on monitoring long-term tolerability and adverse events over several years of administration. This type of research contributes to the overall safety documentation of the medicine.


Q: Why do some people say Soothing didn't work for their condition?

A: Studies and official information indicate that individual responses to the treatment may differ. Research evidence also shows that study conclusions vary based on the specific condition being investigated. The agent's efficacy was primarily examined in trials for individuals with moderate-to-severe symptoms.


Q: Does regulatory information describe Soothing as habit-forming?

A: The product is classified as a Combination Antacid and Local Anesthetic. Official product labels for substances considered habit-forming typically include explicit warnings about dependence, misuse, or abuse. No such classification is noted in the available regulatory documents for this agent.


Q: Can Soothing be used by people with high blood pressure?

A: High blood pressure (hypertension) is not listed in the regulatory documents as a specific contraindication or a condition requiring restriction for use. Conditions that do require specific caution include pre-existing severe hepatic impairment and renal impairment, as detailed in the Eligibility Map.


Q: Are there known interactions between Soothing and common vitamin supplements?

A: The antacid component requires avoiding other oral medications within 1 to 2 hours of administration, a precaution which can extend to some supplements. The safety label also documents the risk of Hypophosphatemia (low phosphate), which may be relevant for dietary and supplement considerations involving minerals.


Q: Is there a limit to how long a person can use Soothing according to official guidelines?

A: Yes, official guidelines specify that use is intended for short-term, symptomatic administration. The regulatory documents state that use should generally not exceed two continuous weeks.

How should Soothing be stored and disposed of?

How to Store and Dispose of Soothing

Official labeling defines precise conditions for the storage and disposal of this combination antacid and local anesthetic oral preparation.

Storage Requirements

  • Temperature and Environment: The medicine must be kept in a cool, dry place, typically stored below 25 C or 30 C, depending on the specific regulatory guidance. It must be protected from direct sunlight, moisture, and heat. Do not refrigerate or freeze the product.
  • Container Integrity: The bottle or container must be kept tightly closed. After the oral suspension is opened, any unused product must be discarded after 4 weeks.
  • Child Safety: It is a mandatory requirement to store the medicine out of the sight and reach of children and away from pets.

️ Disposal Instructions

Unused or expired doses of the medicine must be discarded properly. Regulatory guidelines explicitly state not to flush the product down the toilet or throw it into the drain or wastewater to prevent environmental contamination. If treatment is stopped, the unused medicine should be returned to a pharmacy for formal disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Soothing found in:

A-Z Index: